Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

Registration

Registration

NCT07057310

Study type

INTERVENTIONAL

Allocation

RANDOMIZED

Phase

PHASE4

Masking

SINGLE

Status

ENROLLING_BY_INVITATION

Enrollment

30

Start

2025-05-01

Primary completion

2026-12-31

Lead sponsor

Mayo Clinic

Conditions

Obesity; Menopause

Interventions

DRUG:semaglutide or tirzepatide; BEHAVIORAL:Lifestyle modification intervention

Results posted

FALSE

Individual participant data sharing

NO

Registered primary outcomes

• Physical Function Measure: Short Physical Performance Battery (SPPB) score. [24 weeks]
• Physical Function Measure: Modified Clinical Test of Sensory Interaction in Balance (mCTSIB) performed on the Rehabilitation Artificial Physical Intelligence Database (RAPID) foot pressure mat [24 weeks]
• Physical Function Measure: Standing Chest Throw Test with a 2-kg Weighted Ball using Motion Sensor Technology (MST) [24 weeks]
• Physical Function Measure: Chair-to-Stand Tests using Motion Sensor Technology (MST) [24 weeks]
• Physical Function Measure: Six-Minute Walk Test (6MWT) [24 weeks]
• Physical Function Measure: Hand Grip Strength using a Hydraulic Hand Dynamometer [24 weeks]
• Physical Function Measure: Short Form-12 (SF-12) Health Survey [24 weeks]
• Physical Function Measure: Patient-Reported Outcomes Measurement Information System (PROMIS) - Fatigue and Physical Function Domains [24 weeks]
• Aging Biomarkers: Cellular Senescence Markers in Plasma [24 weeks]
• Difference between biological and chronological age [24 weeks]
• Vascular Function Assessment: Reactive Hyperemia Index (RHI) using EndoPAT [24 weeks]